Pipeline
Autifony’s pipeline includes clinical stage programmes for Schizophrenia, age related hearing loss, Fragile X and earlier stage programmes focused on ALS and Alzheimer’s Disease.
Therapeutic area
Compound
(Target)
(Target)
Indication
Preclinical
Phase 1
Phase 2
Psychiatry
AUT00206
(Kv3.1/3.2)
(Kv3.1/3.2)
Schizophrenia
Neurology
AUT00206
(Kv3.1/3.2)
(Kv3.1/3.2)
Fragile X
Kv3.1
Hearing disorders
Undisclosed target
Alzheimer’s Disease
Related Content
Related News
18Dec
Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders
0 CommentsCollaboration with funding of development activities gives Boehringer Ingelheim exclusive option to purchase certain Autifony assets to treat serious CNS... Read More →
10Jul
Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome
0 CommentsAutifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
18May
Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug
0 CommentsAutifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
10Jan
Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia
0 CommentsAutifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
09Aug
Autifony Announces Results from Completed CLARITY-1, Phase IIa Trial of AUT00063 in Age-related Hearing Loss
0 CommentsAutifony Therapeutics Limited, which is pioneering the development of novel pharmaceutical treatments for hearing disorders and other serious disorders of... Read More →
Tweets
AutifonyLtd @AutifonyLtd
Autifony Therapeutics and Boehringer Ingelheim to collaborate on novel ion channel target with potential in multipl… https://t.co/KMvOWVf9o5
Autifony Therapeutics regains rights to clinical stage Kv3 programme
https://t.co/rBHjjR7aC0
RT @singular_talent:Barbara Domayne-Hayman joined us on Careers in Discovery to talk startups, careers and more.
Barbara's experience… https://t.co/u0VXnvXlGI
Comments are closed.